It's possible and that would be my hope for my investment and maybe even best for the drug prospects. There's a reason independent entities are studying the drug all over the planet. I would prefer the IP in the hands of someone willing to try additional indications.
The company exists to develop their drug platform into a profitable product and not to raise money from investors and then immediately liquidate after a failed trial for one indication.
News 
Market Data 
Discover 
AI
